{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:10Z","timestamp":1792129510869,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:45:30Z","timestamp":1783061130000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline predisposition in myeloproliferative neoplasms"],"prefix":"10.1053","volume":"63","author":[{"given":"Meytal","family":"Chernoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Drazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.006_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the World Health Classification of Tumors of the Hematopoietic and lymphoid tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620713489144","article-title":"Inherited predisposition to myeloproliferative neoplasms","volume":"4","author":"Jones","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.006_bib0004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3324\/haematol.2023.283950","article-title":"Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia","volume":"110","author":"Patel","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.006_bib0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of MPNs: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082100","article-title":"Clonal hematopoiesis and mutations of myeloproliferative neoplasms","volume":"12","author":"Kj\u00e6r","year":"2020","journal-title":"Cancers"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.06.006_bib0008","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0009","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0011","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PPO.0000000000000013","article-title":"Genetics of myeloproliferative neoplasms","volume":"20","author":"Viny","year":"2014","journal-title":"Cancer J Sudbury Mass"},{"issue":"9464","key":"10.1053\/j.seminhematol.2026.06.006_bib0013","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1053\/j.seminhematol.2026.06.006_bib0014","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.006_bib0017","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0018","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0019","first-page":"5155","article-title":"Chemoresistance in breast cancer: pI3K\/Akt pathway inhibitors vs the current chemotherapy","volume":"11","author":"Kaboli","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0021","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/cas.14503","article-title":"Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin","volume":"111","author":"Edahiro","year":"2020","journal-title":"Cancer Sci"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.06.006_bib0022","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/cancers17213397","article-title":"Challenges in the evolving role of calreticulin as a promising target for precision medicine in myeloproliferative neoplasms","volume":"17","author":"Costa","year":"2025","journal-title":"Cancers"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.06.006_bib0023","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.006_bib0024","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2017.01.050","article-title":"JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms","volume":"451","author":"O\u2019Sullivan","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0026","first-page":"163","article-title":"The MPL mutation","volume":"365","author":"Guglielmelli","year":"2021"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0027","first-page":"211","article-title":"Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies","volume":"23","author":"Roloff","year":"2021","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.006_bib0028","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2016.10.003","article-title":"Genetic predisposition to leukemia and other hematologic malignancies","volume":"43","author":"Feurstein","year":"2016","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0029","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.006_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/jcp-2024-210022","article-title":"Fifth edition WHO classification: myeloid neoplasms","volume":"78","author":"Chen","year":"2025","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.006_bib0031","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ajh.70072","article-title":"CHEK2 Germline variants in early-onset and familial myeloproliferative neoplasms","volume":"100","author":"Borsani","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0032","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-025-01433-3","article-title":"Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms","volume":"16","author":"Meyer","year":"2026","journal-title":"Blood Cancer J"},{"issue":"35","key":"10.1053\/j.seminhematol.2026.06.006_bib0033","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.06.006_bib0034","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/bloodadvances.2021004811","article-title":"Germline variants in DNA repair genes, including BRCA1\/2, may cause familial myeloproliferative neoplasms","volume":"5","author":"Elbracht","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.006_bib0035","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/bloodadvances.2024013661","article-title":"JAK2 p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms","volume":"9","author":"Stewart","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0036","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.006_bib0037","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41375-022-01797-6","article-title":"Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms","volume":"37","author":"Braunstein","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0038","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.006_bib0039","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.2023023787","article-title":"The JAK2 46\/1 haplotype influences PD-L1 expression","volume":"145","author":"Carre\u00f1o-Tarragona","year":"2025","journal-title":"Blood"},{"issue":"7831","key":"10.1053\/j.seminhematol.2026.06.006_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0041","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3390\/cells10102597","article-title":"The genetic makeup of myeloproliferative neoplasms: role of germline variants in defining disease risk, phenotypic diversity and outcome","volume":"10","author":"Masselli","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.006_bib0042","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/leu.2017.28","article-title":"Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome\/acute leukemia predisposition syndromes","volume":"31","author":"Guidugli","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107566","article-title":"Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes","volume":"146","author":"Lim","year":"2024","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.006_bib0044","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2015-09-668673","article-title":"Germline RBBP6 mutations in familial myeloproliferative neoplasms","volume":"127","author":"Harutyunyan","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.006_bib0045","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0046","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family history and risk of breast cancer: an analysis accounting for family structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0047","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"The Prostate"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0048","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1111\/j.1572-0241.2001.04677.x","article-title":"A systematic review and meta-analysis of familial colorectal cancer risk","volume":"96","author":"Johns","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0049","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/hematology.2019000047","article-title":"Diagnostic workflow for hereditary erythrocytosis and thrombocytosis","volume":"2019","author":"McMullin","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.06.006_bib0050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3324\/haematol.2017.176370","article-title":"New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis","volume":"103","author":"Pasquier","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.006_bib0051","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.006_bib0052","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2018-06-858597","article-title":"Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms","volume":"132","author":"Sud","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.06.006_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012582","article-title":"The contribution of JAK2 46\/1 haplotype in the predisposition to myeloproliferative neoplasms","volume":"23","author":"Paes","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.006_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031013","article-title":"Insights into the potential mechanisms of JAK2V617F somatic mutation contributing distinct phenotypes in myeloproliferative neoplasms","volume":"23","author":"Gou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.06.006_bib0055","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ajh.23842","article-title":"Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms","volume":"89","author":"J\u00e4ger","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0056","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41588-025-02250-x","article-title":"Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy","volume":"57","author":"Liu","year":"2025","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.006_bib0057","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/jgc4.1672","article-title":"Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies","volume":"32","author":"Roloff","year":"2023","journal-title":"J Genet Couns"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.006_bib0058","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.hoc.2012.07.005","article-title":"Role of germline genetic factors in MPN pathogenesis","volume":"26","author":"Harutyunyan","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0059","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-025-02814-0","article-title":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study","volume":"40","author":"Gurnari","year":"2026","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.108118","article-title":"Applicability of current prognostication models for MDS patients with DDX41 mutation","volume":"158","author":"Toumeh","year":"2025","journal-title":"Leuk Res"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.06.006_bib0061","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1182\/bloodadvances.2025017084","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies","volume":"9","author":"Loschi","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.006_bib0062","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clml.2023.01.011","article-title":"SOHO State of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it","volume":"23","author":"Patel","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.06.006_bib0063","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.06.006_bib0064","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/blood-2015-04-639039","article-title":"Survival in patients with familial and sporadic myeloproliferative neoplasms","volume":"125","author":"Hultcrantz","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.06.006_bib0065","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2016-05-670240","article-title":"The University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies","volume":"128","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.006_bib0066","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.3324\/haematol.2023.284584","article-title":"Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation","volume":"109","author":"Roloff","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.006_bib0067","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.006_bib0068","article-title":"ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Miller","year":"2023","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0069","series-title":"GeneReviews\u00ae","article-title":"CHEK2-Related cancer predisposition","author":"Hanson","year":"1993"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0070","unstructured":"BRCA Gene Changes: Cancer risk and genetic testing fact sheet - NCI. 2024. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet. Accessed April 7, 2026."},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.006_bib0071","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.3324\/haematol.2024.285055","article-title":"Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings","volume":"109","author":"Ceyhan-Birsoy","year":"2024","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0072","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis","author":"Hoffman","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.06.006_bib0073","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"},{"issue":"32","key":"10.1053\/j.seminhematol.2026.06.006_bib0074","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.06.006_bib0075","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving toward disease modification in polycythemia vera","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.006_bib0076","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia Vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.06.006_bib0077","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0078","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.70105","article-title":"Coexisting myeloproliferative and lymphoid neoplasms: a European multicenter retrospective study","volume":"101","author":"Fiallo-Su\u00e1rez","year":"2026","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.006_bib0079","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","article-title":"Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","volume":"35","author":"Singhal","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.006_bib0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.24374","article-title":"Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders","volume":"43","author":"DeRoin","year":"2022","journal-title":"Hum Mutat"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.06.006_bib0081","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/bloodadvances.2020002803","article-title":"Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy","volume":"4","author":"Aldoss","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.006_bib0082","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.06.006_bib0083","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/bloodadvances.2022007211","article-title":"Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations","volume":"6","author":"Drazer","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.06.006_bib0084","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.06.006_bib0085","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood-2022-156781","article-title":"JAK2V617F Molecular response to ruxolitinib in patients with PV and ET is associated with lower risk of progression to secondary myelofibrosis","volume":"140","author":"Guglielmelli","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.006_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100696","article-title":"PARP goes the weasel! emerging role of PARP inhibitors in hematological malignancies","volume":"45","author":"Fritz","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0087","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.006_bib0088","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.24946","article-title":"MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: a study on 939 patients","volume":"93","author":"Trifa","year":"2018","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.06.006_bib0089","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133246","article-title":"Germline ERBB2\/HER2 coding variants are associated with increased risk of myeloproliferative neoplasms","volume":"13","author":"Braunstein","year":"2021","journal-title":"Cancers"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:57:47Z","timestamp":1792126667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000697"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline predisposition in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}